{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T19:03:54Z","timestamp":1777575834611,"version":"3.51.4"},"reference-count":12,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T00:00:00Z","timestamp":1764460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T00:00:00Z","timestamp":1764460800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Votoplam is a novel, orally bioavailable, small molecule HTT gene splicing modifier that is being developed for the treatment of Huntington's disease. This was a single dose, open\u2010label, two\u2010period, crossover food effect study that evaluated the effect of high\u2010 and low\u2010fat meals on 20\u00a0mg votoplam in healthy participants. There was a washout of 21 days between the two periods. Twenty\u2010six participants completed the study. There were minimal changes in the bioavailability and pharmacokinetics of votoplam following administration of a single dose of 20\u00a0mg votoplam when taken with low\u2010fat and high\u2010fat meals relative to fasted condition. The mean C\n                    <jats:sub>max<\/jats:sub>\n                    , AUC\n                    <jats:sub>0\u2013last<\/jats:sub>\n                    , and AUC\n                    <jats:sub>0\u2013inf<\/jats:sub>\n                    for votoplam following administration of a single dose of 20\u00a0mg votoplam were 1.4\u2010fold, 1.2\u2010fold, and 1.1\u2010fold higher, respectively, in high\u2010fat fed conditions, and were 1.3\u2010fold, 1.1\u2010fold, and 1.1\u2010fold higher, respectively, in the low\u2010fat fed conditions, when compared to fasted conditions. There were no relevant safety findings in any of the treatment groups. Votoplam can be administered with or without food in patients.\n                  <\/jats:p>","DOI":"10.1002\/cpdd.1626","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T05:58:22Z","timestamp":1764568702000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of High\u2010 and Low\u2010Fat Meals on the Bioavailability and Pharmacokinetics of Votoplam, a HTT Gene Splicing Modifier"],"prefix":"10.1002","volume":"15","author":[{"given":"Lucy","family":"Lee","sequence":"first","affiliation":[{"name":"PTC Therapeutics, Inc.  Warren NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy\u2010Lee","family":"Richards","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc.  Warren NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nageswara","family":"Reddy","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc.  Warren NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Beers","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc.  Warren NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee","family":"Golden","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc.  Warren NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Kong","sequence":"additional","affiliation":[{"name":"PTC Therapeutics, Inc.  Warren NJ USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,11,30]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"1993","volume-title":"GeneReviews\u00ae","author":"Caron NS","year":"1998"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2014.24"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prdoa.2020.100056"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a024240"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1326-1-19"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-020-0389-4"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2020.0299"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27157-z"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00741"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn1806"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.16202"},{"key":"e_1_2_8_13_1","volume-title":"Assessing the Effects of Food on Drugs in Investigational New Drugs and New Drug Applications\u2010Clinical Pharmacology Considerations; Guidance for Industry","author":"U.S. Food and Drug Administration","year":"2022"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1626","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpdd.1626","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1626","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T13:48:32Z","timestamp":1774360112000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.1626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,30]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1002\/cpdd.1626"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.1626","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,30]]},"assertion":[{"value":"2025-09-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e1626"}}